Carvedilol Tablet, Film Coated
Product Images NDC 68071-4816

6 FDA label images from Nucare Pharmaceuticals,inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 68071-4816). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pdp (68071 4816 8)

Pdp (68071 4816 8)
Carvedilol 6.25 mg film-coated tablets label by NuCare Pharmaceuticals, Inc. This prescription drug packaging indicates a count of 180 tablets. The label details a circular white tablet engraved with 'G' and '41'. It includes NDC 68071-4816 and advises to keep the product out of reach of children and store at controlled temperature 68-77°F.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph comparing mortality percentage over 21 months between Carvedilol and placebo groups. The x-axis shows months, and the y-axis shows percentage mortality. The Carvedilol group has consistently lower mortality than the placebo group, with a statistical significance indicated by P = 0.0014.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A hazard ratio forest plot showing treatment effects of Carvedilol across various patient subgroups, including men, women, age groups, race, diabetic status, ischemic conditions, heart rate categories, systolic blood pressure levels, and spironolactone usage, with confidence intervals indicated for each subgroup.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A survival analysis line graph titled 'Survival Analysis for CAPRICORN (intent-to-treat)' showing percentage mortality over 24 months. The graph compares two groups labeled 'Placebo' and 'Carvedilol,' with Carvedilol showing lower mortality over time. A p-value of 0.03 is noted on the graph, indicating statistical significance between the groups.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A forest plot titled 'Figure 4. Effects on Mortality for Subgroups in CAPRICORN' showing hazard ratios for mortality across various patient subgroups. Subgroups include age, sex, randomization timing post-myocardial infarction, prior beta-blocker use, Killip class, thrombolytic treatment, PTCA for MI, heart failure history, diuretic use, angina, hypertension, diabetes, heart rate, and systolic blood pressure. Hazard ratios with confidence intervals are plotted comparing subgroups against a reference line at hazard ratio 1.0.*
FDA Label Image

Carvedilol-chemical-structure (Structure)

Carvedilol-chemical-structure (Structure)
Chemical structure of carvedilol, depicting its molecular framework including aromatic rings, hydroxyl, ether, and amine functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.